The Swiss asthma drug developer's stock soared past its IPO price, even though its lead drug has no proof yet that it prevents attacks.
Read the full story →
#Biotech #WindwardBio #TheDailyFathom
The Swiss asthma drug developer's stock soared past its IPO price, even though its lead drug has no proof yet that it prevents attacks.
Read the full story →
#Biotech #WindwardBio #TheDailyFathom
https://www.narrowit.com/news/windward-bio-nasdaq-ipo-clinical-pipeline-2026-11-15
#WindwardBio #WWB #IPO #Nasdaq
https://www.narrowit.com/news/windward-bio-nasdaq-ipo-clinical-pipeline-2026-11-15
#WindwardBio #WWB #IPO #Nasdaq
pharmaphorum.com/news/windwar...
pharmaphorum.com/news/windwar...
pharmaphorum.com/news/windwar...
pharmaphorum.com/news/windwar...